Non-proliferative diabetic retinopathy
KODKodiak Sciences Inc.Catalyst overview
Research summary
This catalyst tracks a BLA submission for Tarcocimab (KSI-301) (anti-VEGF) in Non-proliferative diabetic retinopathy. The expected timing is based on the latest available company guidance and may change.
GLOW1 & 2 study. 11/06/23- Rebooted the program due to high statistical significance. Could support single BLA application. 5/14/24 First patient treated in GLOW2. Data at ARVO '24 on May 6th 2024. 3/10/25- Complete enrollment in second registrational study, GLOW2 data expected in Q1 2026. 11/13/25:- GLOW2 enrollment complete; topline diabetic retinopathy data remains on track for Q1 2026. 03/26/26:- GLOW2 Phase 3 topline results positive; plans to accelerate BLA submission timeline. 03/31/26:- GLOW2 Ph3 showed strong DRSS improvements and reduced complications; Zenkuda now described as multi-indication BLA-ready. 05/07/26:- GLOW2 detailed Phase 3 results confirm strong DRSS improvements, reduced sight-threatening complications and clean ocular safety.
Verification
Confirm timing and program details against the company announcement or filing.